Physician profile
Emily E Alliss
NPI 1982328530
$2,913.46
in general payments reported to CMS, 2019-2025
10 companies · $905 in 2025
The $905 reported for 2025 was more than what 86% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $118 · 2024: $1,890 · 2025: $905.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,781 · Travel and Lodging: $884 · Education: $130.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,781.28 |
| Travel and Lodging | $883.93 |
| Education | $130.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,998.27 | 2022-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia, Hemosphere |
| Medtronic, INC. | $544.96 | 2024-2025 | Symplicity G3 |
| Abiomed | $88.17 | 2022 | |
| Novartis Pharmaceuticals Corporation | $79.09 | 2024-2025 | |
| Amgen INC. | $70.38 | 2025 | Repatha |
| Heartflow, INC. | $51.11 | 2025 | |
| Novo Nordisk INC | $23.23 | 2025 | Wegovy |
| Kiniksa Pharmaceuticals International, Plc | $23.11 | 2024 | Arcalyst |
| Janssen Pharmaceuticals, INC | $21.62 | 2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $13.52 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Alliss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.